Selecting antibacterial agents for the control of surgical infection: Mini-review

Journal of Chemotherapy

Volumn 10, Issue 2, 1998, Pages 83-90

  Periti, P ^a,b   Tonelli, F ^a   Mini, E ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b NONE   (Italy)

Author keywords

Antimicrobial prophylaxis; Prophylaxis for surgical infections; Sepsis; Septic shock; Surgical antimicrobial prophylaxis; Surgical infectiomns

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; CEFAMANDOLE; CEFAZOLIN; CEFODIZIME; CEFONICID; CEFOTETAN; CEFTRIAXONE; CEFUROXIME; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC SENSITIVITY; ANTISEPSIS; BACILLUS; CORYNEBACTERIUM; ENTEROBACTERIACEAE; GRAM NEGATIVE BACTERIUM; HEART SURGERY; HUMAN; IN VITRO STUDY; NEUROSURGERY; ORTHOPEDIC SURGERY; PLASTIC SURGERY; POSTOPERATIVE INFECTION; PROSTHESIS; REVIEW; SEPTIC SHOCK; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; SURGICAL INFECTION; SURGICAL TECHNIQUE; VASCULAR SURGERY; WOUND INFECTION;

EID: 0031896672     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.1998.10.2.83     Document Type: Review

References (65)

1. Periti P, Mazzei T. Principles of antimicrobial chemoprophylaxis in surgery. Chemioterapia 1987; VI (3): 196-201.
2. Caputo GM, Singer M, White S, et al. Infections due to antibiotic-resistant Gram-positive cocci. J Intern Med 1993; 8: 626-634.
3. Neu HC. Emerging trends in antimicrobial resistance in surgical infections. A review. Eur J Surg 1994; Suppl 573: 7-18.
4. Thornsberry C. Epidemiology of staphylococcal infections. A USA perspective. J Chemother 1994; 6 (Suppl 2): 61-65.
5. Voss A, Milatovic D, Wallrauch-Schwarz C, et al. Methicillin-resistant Staphylococcus aureus in Europe. Eur J Clin Microbiol Infect Dis 1994; 13: 50-55.
6. Cruse PJE, Foord R. A five-year prospective study of 23,649 wounds. Arch Surg 1973; 107: 206-210.
7. Page CP, Bohnen JM, Fletcher R, et al. Antimicrobial prophylaxis for surgical wounds. Guidelines for clinical care. Arch Surg 1993; 128: 79-88.
8. Culver DH, Horav TC, Gaynes RP. et al. National nosocomial infections surveillance system: surgical wound infection rates by wound class operative procedure, and patient risk index. Am J Med 1991; 91 (Suppl 3B): 152-157.
9. Garibaldi RA, Cushing D, Lerer T. Risk factors for postoperative infection. Am J Med 1991; 91 (Suppl 3B): 158-163.
10. 1Sherentz RJ, Morosok RD, Garibaldi RA, et al. Consensus paper on the surveillance of surgical wound infections. The Society of Hospital Epidemiology of America, the Association for Practitioners in Infection Control, the Centers for Disease Control, the Surgical Infection Society. Infect Control Hosp Epidemiol 1992; 13: 599-605.
11. American Medical Association. Drug Evaluations Annual 1994. Antimicrobial chemoprophylaxis for surgical patients 1994; 32: 1317-1321.
12. American Society of Hospital Pharmacists Commission on Therapeutics. ASHP therapeutic guidelines on antimicrobial prophylaxis in surgery. Clin Pharmacokinet 1992; 11: 483-513.
13. Anonymous. Antimicrobial prophylaxis in surgery. Med Lett Drugs Ther 1995; 37: 79-82.
14. Burnakis TG. Surgical antimicrobial prophylaxis: principles and guidelines. Pharmacotherapy 1984; 4: 248-271.
15. Gorbach SL, Condon RE, Conte Jr-JE, et al. Evaluation of new anti-infective drugs for surgical prophylaxis. Clin Infect Dis 1992; 15 (Suppl 1): S313-S338.
16. Hopkins CC. Antibiotic prophylaxis in clean surgery: peripheral vascular surgery, noncardiovascular thoracic surgery, herniorrhaphy, and mastectomy. Rev Infect Dis 1991; 13 (Suppl 10): S869-S873.
17. Kernodle DS, Kaise AB. Postoperative infections and antimicrobial prophylaxis. In: Principles and Practice of Infectious Diseases, Mandell GL, Bennert JD, Dolin R, Eds, 4th ed. New York: Churchill Livingstone, 1995: 2742-2756.
18. Nichols RC. Antibiotic prophylaxis in surgery. Curr Opin Infect Dis 1994; 7: 647-652.
19. Strachan CJL. Antibiotic prophylaxis in 'clean' surgical procedures. World J Surg 1982; 6: 273-280.
20. Strachan CJL. Antibiotic prophylaxis in peripheral vascular and orthopaedic prosthetic surgery. J Antimicrob Chemother 1993; 31 (Suppl B): 65-78.
21. Dickinson GM, Bisno AL. Antimicrobial prophylaxis of infection. Infect Dis Clin North Am 1995; 9: 783-804.
22. Haas DW, Kaiser AB. Antimicrobial prophylaxis of infections associated with foreign bodies. In: Infections Associated with Indwelling Medical Devices, Bisno AL, Waldvogel FA, Eds. Washington DC: American Society for Microbiology Press, 1994: 375.
23. Mini E, Nobili S, Periti P. Methicillin-resistant staphylococci in clean surgery. Is there a role for prophylaxis? Drugs 1998, Suppl in press.
24. Classen DC, Evans RS, Pestotnik SL, et al. The timing of prophylactic administration of antibiotics and the risk of surgical wound infection. N Engl J Med 1992; 326: 281-286.
25. Sanderson PJ. Antimicrobial prophylaxis in surgery: microbiological factors. J Antimicrob Chemother 1993; 31 (Suppl B): 1-9.
26. Bisno AL, Waldvogel FA, (Eds). Infections Associated with Indwelling Medical Devices. American Society for Microbiology, Washington DC 1989.
27. Sugarman B, Young EJ, (Eds). Infections Associated with Prosthetic Devices. CRC Press, Boca Raton, Florida 1984.
28. Eng RHK, Hsieh A, Smith SM. Antibiotic killing of bacteria: comparison of bacteria on surfaces and in liquid, growing and nongrowing. Chemotherapy 1995; 41: 113-120.
29. Christensen GD, Simpson WA, Bison AL, et al. Adherence of slime producing strains of Staphylococcus epidermidis to smooth surfaces. Infect Immun 1982; 37: 318-326.
30. Peters G, Locci R, Pulvever G. Adherence and growth of coagulase-negative staphylococci on surfaces of intravenous catheters. J Infect Dis 1982; 146: 479-482.
31. Periti P. Preclinical and clinical evaluation of once-daily aminoglycoside chemotherapy. J Chemother 1995; 7 (4): 311-337.
32. Dougherty SH. Implant infections. In: Hand Book of Biomaterials Evaluation, VonRecum F, Ed. New York: MacMillan, 1986: 276-287.
33. Cartel LL, Dutton RW. Type 1 and Type 2: a fundamental dichotomy for all T-cell subsets. Curr Opin Immunol 1996; 8: 336-342.
34. Casadevall A. Crisis in infectious diseases: time for a new paradigm? Clin Infect Dis 1996; 23: 790-794.
35. Tracey Kj, Cerami A. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu Rev Med 1994; 45: 491-503.
36. Suter PM, Suter S, Giradin E, Roux-Lombard P, Grau GE, Dayer JM. High bronchoalveolar levels of tumor necrosis factor and its inhibitor, interleukin-1, interferon and elastase in patients with adult respiratory distress syndrome after trauma, shock or sepsis. Am Rev Respir Dis 1992; 145: 1016-1022.
37. Zabel P, Schade FU. Pentoxifylline and tumour necrosis factor-induced lung injury. Eur Respir J 1994; 7: 1389-1391.
38. Mohler J, Fantin B, Mainardi JL, Carbon C. Influence of antimicrobial therapy on kinetics of tumor necrosis factor levels in experimental endocarditis caused by Klebsiella pneumoniae. Antimicrob Agents Chemother 1994; 38: 1017-1022.
39. Horn DL, Opal SM, Lomastro E. Antibiotics, cytokines, and endotoxin: a complex and evolving relationship in Gramnegative sepsis. Scand J Infect Dis 1996; Suppl 10: 9-13.
40. Kusser WC, Ishiguro EE. Effects of aminoglycosides and spectinomycin on the synthesis and release of lipopolysaccharide by Escherichia coli. Antimicrob Agents Chemother 1988; 32: 1247-1250.
41. Focà A, Matera G, Iannello D, Berlinghieri MC, Liberto MC. Aminoglycosides modify the in vitro metachromatic reaction and murine generalized Shwartzman phenomenon induced by Salmonella minnesota R595 lipopolysaccharide. Antimicrob Agents Chemother 1991; 35 (10): 2161-2164.
42. Focà A, Matera G, Berlinghieri MC, Liberto MC, De Sarro GB. Teicoplanin reduces in-vitro reactivity and murine lethality of Salmonella minnesota R595 lipopolysaccharide. J Antimicrob Chemother 1992; 29: 443-446.
43. Focà A, Matera G, Berlinghieri MC. Inhibition of endotoxin-induced interleukin 8 release by teicoplanin in human whole blood. Eur J Clin Microbiol Infect Dis 1993; 12: 940-944.
44. Kirikae T, Nakano M, Morrison DC. Antibiotic-induced endotoxin release from bacteria and its clinical significance - Review. Microbiol Immunol 1997; 41 (4): 285-294.
45. Kadurugamuwa JL, Beveridge TJ. Natural release of virulence factors in membrane vesicles by Pseudomonas aeruginosa and the effect of aminoglycoside antibiotics on their release. J Antimicrob Chemother 1997; 40: 615-621.
46. Siedlar M, Szczepanik A, Wieckiewicz J, Pituch-Noworolska A, Zembala M. Vancomycin down-regulates lipopolysaccharide-induced tumour necrosis factor alpha (TNFα) production and TNFα-mRNA accumulation in human blood monocytes. Immunopharmacology 1997; 35: 265-271.
47. Labro MT. The prohost effect of antimicrobial agents as a predictor of clinical outcome. J Chemother 1997; 9 (Suppl 1): 100-108.
48. Periti P. Immunofarmacologia di betalattamine parenterali. Farm Ter 1997; XIV (3/4): 56-67.
49. Mattsson E, Verhage L, Rollof J, Fleer A, Verhoek J, Van Dijk H. Peptidoglycan and teichoic acid from Staphylococcus epidermidis stimulate human monocytes to release tumour necrosis factor-alpha, interleukin-1 beta and interleukin-6. FEMS Immunol Med Microbiol 1993; 7: 281-287.
50. Heumann D, Barras C, Severin A, Glauser MP, Tomasz A. Gram-positive cell walls stimulate synthesis of rumor necrosis factor alpha and interleukin-6 by human monocytes. Infect Immun 1994; 62: 2715-2721.
51. Debets JMH, Kampmeijer R, Van der Linden MPH, Burman WA, Van der Linden CJ. Plasma tumor necrosis factor and mortality in critically ill septic patients. Crit Care Med 1989; 17: 489-493.
52. Malhotra R, Bird MI. L-selection: a novel receptor for lipopolysaccharide and its potential role in bacterial sepsis. BioEssays 1997; 19 (10): 919-923.
53. Hurley JC. Antibiotic-induced release of endotoxin: a reappraisal. Clin Infect Dis 1992; 15: 840-854.
54. Horn DL, Opal SM, Lonastro E. Antibiotics, cytokines, and endotoxin: a complex and evolving relationship in Gram-negative sepsis. Scand J Infect Dis 1996; Suppl 101: 9-13.
55. Jackson JJ, Kropp H. Betea-lactam antibiotic-induced release of free endotoxin: in vitro comparison of penicillin-binding protein (PBP)-2-specific imipenem and PBP-3-specific ceftazidime. J Infect Dis 1992; 165: 1033-1041.
56. Prins JM, van Agtmael MA, Kuijper EJ, van Deventer SJH, Speelman P. Antibiotic-induced endotoxin release in patients with Gram-negative urosepsis: a double-blind study comparing imipenem and ceftazidime. J Infect Dis 1995; 172: 886-891.
57. Eng RHK, Smith SM, Fan-Havard P, Ogbara T. Effect of antibiotics on endotoxin release from Gram-negative bacteria. Diag Microbiol Infect Dis 1993; 16: 185-189.
58. Gårdlund B, Sjölin J, Nilsson A, Roll M, Wickerts CJ, Wretlind B. Plasma levels of cytokines in primary septic shock in humans: correlation with disease severity. J Infect Dis 1995; 172: 296-301.
59. Hack CE, Hart M, Strack van Schijndel RJM, et al. Interleukin-8 in sepsis: relation to shock and inflammatory mediators. Infect Immun 1992; 60: 2835-2842.
60. Beutler B, Cerami A. Tumor necrosis, cachexia, shock, and inflammation: a common mediator. Annu Rev Biochem 1988; 57: 505-518.
61. Lynn WA. Anti-endotoxin therapeutic options for the treatment of sepsis. J Antimicrob Chemother 1998; 41 (Suppl A): 71-80.
62. Gupta D, Jin Y-P, Dziarski R. Peptidoglycan induces transcription and secretion of TNFα and activation of lyn, extracellular signal-regulated kinase, and rsk signal transduction proteins in mouse macrophages. J Immunol 1995; 155: 2620-2630.
63. Kragsbjerg P, Holmberg H, Vikerfors T. Dynamics of blood cytokine concentrations in patients with bacteremic infections. Scand J Infect Dis 1996; 28: 391-398.
64. Endo S, Inada K, Kikuchi M, et al. Clinical effects of intramuscular administration of a small dose of polymyxin B to patients with endotoxemia. Res Comm Chem Pathol Pharm 1994; 83 (2): 223-235.
65. Periti P. Introduction: cephalosporin generations. J Chemother 1996; 8 (Suppl 2): 3-6.